Aktywność biologiczna pochodnych 2,7-naftyrydyny

• Autorzy: Wójcicka A. , Wagner E.

Warianty tytułu

EN

Biological activity of 2,7-naphthyridine derivatives

• Języki publikacji: PL

Abstrakty

EN

2,7-Naphthyridine is one of the six structural isomers of pyridopyridines. More than one hundred years ago, Gabriel and Colman discovered the isomer 2,7-naphthyridine, and named it “copiryne” [3]. From among of all naphthyridines, the synthesis and properties of the copyrine derivatives have not yet been thoroughly investigated. This paper reviews the synthetic and natural 2,7-naphthyridine derivatives which have been reported to possess various biological activity. A large number alkaloids containing the 2,7-naphthyridine scaffold have been isolated from plants and marine organisms [13–18]. The natural marine alkaloids can be classified into two groups. The bicyclic lophocladines were isolated from the red alga Lophocladia sp. [12]. The pyridoacridines represent a large and growing class the polycyclic alkaloids from sponges, ascidians or tunicates [15, 16]. Many of this natural compounds exhibited cytotoxic, antibacterial, antiviral, antifungal and sedative activity. The broad spectrum of biological activity of copyrine alkaloids is the main of reason for the preparation of new 2,7-naphthyridine derivatives also by the synthetic route. So far, about fifty different methods of synthesizing the 2,7-naphthyridine ring have been published. This study described synthesis only biologically active 2,7-naphthyridine analogues. Biological investigations have shown that copyrine derivatives have a wide spectrum of actions. Antitumor, antimicrobial, analgesic and anticonvulsion activities have been found. Most of 2,7-naphthyridine derivatives have been studied as antitumor agents. Many papers described synthesis and pharmacological properties the best active and highly selective PDE5 inhibitor (T-0156) [55]. So far, none of 2,7-naphthyridine derivatives has been applied as a drug.

Słowa kluczowe

PL

pochodne 2,7-naftyrydyny; aktywność biologiczna

EN

2,7-naphthyridine derivatives; biological activity

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Wiadomości Chemiczne
• Rocznik: 2011
• Tom: [Z] 65, 3-4
• Strony: 235--264
• Opis fizyczny: Bibliogr. 66 poz., schem.

Twórcy

autor

Wójcicka A.

autor

Wagner E.

• Katedra i Zakład Technologii Leków, Akademia Medyczna im. Piastów Śląskich we Wrocławiu, pl. Nankiera 1, 50-140 Wrocław,

Bibliografia

• [1] W.W. Paudler, T.J. Kress, Adv. Heterocyclic Chem., 1970, 11, 123.
• [2] G.Y. Lesher, E.J. Froelich, M.D. Gruett, J.H. Bailery, R.P. Brundage, J. Med. Pharm. Chem., 1962, 91, 1063.
• [3] S. Gabriel, J. Colman, Chem. Ber., 1902, 35, 1358.
• [4] J .W. Huff, J. Biol. Chem., 1947, 164, 151.
• [5] J .U. Rao, G.S Giri, T. Hanumaiah, K.V.J. Rao, J. Nat. Prod., 1986, 49, 346.
• [6] F. Bracher, Liebigs Ann. Chem., 1989, 1, 87.
• [7] S.C. Liu, B. Oguntimein, C.D. Hufford, Antimicrob. Agents Chemother., 1990, 34, 529.
• [8] J .R. Peterson, J.K. Zjawiony S. Liu, C.D. Hufford, A.M. Clark, R.D. Rogers, J. Med. Chem., 1992, 35, 4069.
• [9] I. Muhammad, D.C. Dunbar, S. Takamatsu, L.A. Walker, A.M. Clark, J. Nat. Prod., 2001, 64, 559.
• [10] J . Kluza, R. Mazinghien, K. Degardin,. A. Lansiaux, C. Bailly, Eur. J. Pharm., 2005, 525, 32.
• [11] M. Janot, J. Guilhem, O. Coutz, E. Venera, E. Clonga, Ann. Pharm. Fr., 1979, 37, 413.
• [12] H. Gross, D.E. Goeger, P. Hills, S.L. Mooberry, D.L. Balantine, T.F. Murray, F.A. Valeriote, W.H. Gerwick, J. Nat. Prod., 2006, 69, 640.
• [13] M. Lotter, J. Schilling, E. Reimann, F. Bracher, Arch. Pharm. Chem. Life Sci., 2006, 339, 677.
• [14] F. J. Schmitz, S.K. Agarwal, P.G. Schmidt, S.P. Gunasekera, J.N. Schooley, J. Am. Chem. Soc., 1983, 105, 4835.
• [15] T.F. Moliński, Chem. Rev., 1993, 93, 1825.
• [16] E. Delfourne, J. Bastide, Med. Res. Rev., 2003, 23, 234.
• [17] F.S. Guzman, B. Carte, N. Troupe, D.J. Faulkner, M.K. Harper, G.P. Concepcion, G.C. Mangalindan, S.S. Matsumoto, L.R. Barrows, C.M. Ireland, J. Org. Chem., 1999, 64, 1400.
• [18] D. Tasdemir, K.M. Marshall, G.C. Mangalindan, L.R. Barrows, M.K. Harper, C.M. Ireland, J. Org. Chem., 2001, 66, 3246.
• [19] A.M. Echavarren, J.K. Stille, J. Am. Chem. Soc., 1988, 110, 405.
• [20] A. Kubo, S. Nakahara, Heterocycles, 1988, 27, 2095.
• [21] R.H. Prager, C. Tsopelas, Heterocycles, 1989, 29, 847.
• [22] J . Kobayashi, J. Cheng, H. Nakamura, Y. Ohizumi, Tetrahedron Lett., 1988, 29, 1177.
• [23] C.J. Moody, C.W. Rees, R. Thomas, Tetrahedron Lett., 1990, 31, 4375.
• [24] C.J. Moody, C.W. Rees, R. Thomas, Tetrahedron, 1992, 48, 3589.
• [25] Y. Feng, A. Rohan, R.A. Davis, M.L. Sykes, V.M. Avery, A.R. Carroll, D. Camp, R.J. Quinn, Tetrahedron Lett., 2010, 51, 2477.
• [26] N. Bontemps, D. Bry, S. Lopez-Legentil, A. Simon-Levert, C. Long, B. Banaigs, J. Nat. Prod., 2010, 73, 1044.
• [27] D.R. Appleton, A.N. Pearce, B.R. Copp, Tetrahedron, 2010, 66, 4977.
• [28] F.J. Schmitz, F.S. DeGuzman, M.B. Hossain, D. van der Helm, J. Org. Chem.,1991, 56, 804.
• [29] I. Bonnard, N. Bontemps, S. Lahmy, B. Banaigs, G. Combaut, C. Francisco, P. Colson, C. Houssier, C. Bailly, M.J. Waring, Anti-cancer Drug Design, 1995, 10, 333.
• [30] N. Bontemps, I. Bonnard, B. Banaigs, G. Combaut, C. Francisco, Tetrahedron Lett.,1994, 35, 7023.
• [31] Y. Kitahara, F. Tamura, M. Nishimura, A. Kubo, Tetrahedron, 1998, 54, 8421.
• [32] J .A. de la Fuentez, M.J. MartÍn, M.M. Blanco, E. Pascual-Alfonso, C. Avendańo, J.C. Menéndez, Bioorg. Med. Chem., 2001, 9, 1807.
• [33] R.E. Longley, O.J. McConnell, E. Essich, D. Harmody, J. Nat. Prod., 1993, 56, 915.
• [34] A.R. Carroll, P.J. Scheuer, J. Org. Chem.,1990, 55, 4426.
• [35] G.P. Gunawardana, U. Premachandran, N.S. Burres, D.N. Whittern, R. Henry, S. Spanton, J.B. McAlpine, J. Org. Chem., 1992, 57, 1523.
• [36] C. Eder, P. Schupp, P. Proksch, V. Wray, K. Steube, C.E. Muller, W. Frobenius, M. Herderich, J. Nat. Prod., 1998, 61, 301.
• [37] L.A. McDonald, G.S. Elredge, L.R. Barrows, C.M. Ireland, J. Med. Chem., 1994, 37, 3819.
• [38] Y. Kitahara, S. Nakahara, T. Yonezawa, M. Nagatsu, Y. Shibano, A. Kubo, Tetrahedron, 1997, 53, 17029.
• [39] M.J. Bishop, M.A. Ciufolini, J. Am. Chem. Soc., 1992, 114, 1008.
• [40] M.A. Ciufolini, Y.C. Shen, Tetrahedron Lett., 1995, 36, 4709.
• [41] A. Pulbrukarn, B.S. Davidson, J. Org. Chem., 1998, 63, 1657.
• [42] B.R. Copp, J. Jompa, A. Tahir, C.M. Ireland, J. Org. Chem., 1998, 63, 8024.
• [43] D. Skyler, C.H. Heathcock, Org. Lett., 2001, 3, 4323.
• [44] T.F. Moliński, E. Fahy, D.J. Faulkner, G.D. Van Duyne, J. Clardy, J. Org. Chem., 1988, 53, 1340.
• [45] A.R. Carroll, A. Ngo, R.J. Quinn, J. Redburn, J.N.A. Hooper, J. Nat. Prod., 2005, 68, 804. 264 A. Wójcic ka, E. Wagner
• [46] E.C. Barnes, N.A.B.M. Said, E.D. Williams, J.N.A. Hooper, R.A. Davis, Tetrahedron, 2010, 66, 283.
• [47] J .A. Clement, M. Li, S.M. Hecht, D.G.I. Kingston, Bioorg. Med. Chem., 2008, 16, 10022.
• [48] E. Delfourne, R. Kiss, L. Le Corre, F. Dujols, J. Bastide, F. Collignon, B. Lesur, A. Frydman, F. Darro, Bioorg. Med. Chem., 2004, 12, 3987.
• [49] K . Gorlitzer, Ch. Bonnekessel, P.G. Jones, A. Palusczak, R.W. Hartmann, Pharmazie, 2006, 61, 975.
• [50] K . Gorlitzer, C.H. Enge, P.G. Jones, H. Jomaa, J. Wiesner, Pharmazie, 2007, 62, 89.
• [51] A. Gopalsamy, M. Shi, D.H. Boschelli, R. Williamson, A. Olland, J. Med. Chem., 2007, 50, 5547.
• [52] K .H. Kim, Bioorg. Med. Chem., 2009, 19, 5225.
• [53] T. Nattoli, G.R. Dushin, C.I. Cheung, M.B. Floyd, H. Fraser, A. Olland, Y. Hu, G. Grosu, X. Han, K. Arndt, B. Guo, A. Wissner, Eur. J. Med. Chem., 2010, 45, 1379.
• [54] K . Kikkawa, T. Noto, K. Yano, H. Inoue, H. Mochida, M. Takagi, Jpn. J. Pharmacol., 2001, 85, 282P.
• [55] H. Mochida, M. Takagi, H. Inoue, T. Noto, K. Yano, K. Fujishige, T. Sasaki, K. Yuasa, J. Kotera, K. Omori, Eur. J. Pharm., 2002, 456, 91.
• [56] T. Ukita, Y. Nakamura, A. Kubo, Y. Yamamoto, Y. Moritani, K. Saruta, T. Higashijima, Bioorg. Med. Chem. Lett., 2003, 13, 2341.
• [57] Y. Ikeura, T. Tanaka, Y. Kiyota, S. Morimoto, M. Ogino, T. Ishimaru, I. Kamo, T. Doi, H. Natsugari, Chem. Pharm. Bull., 1997, 45, 1642.
• [58] E. Wagner, A. Wójcicka, I. Bryndal, T. Lis, Polish J. Chem., 2009, 83, 207.
• [59] A. Gangjee, J. Shi, S.F. Queener, J. Med. Chem., 1997, 40, 1930.
• [60] Y. Yao, Y. Sei, M.P. Abbracchio, J.-L. Jiang, Y.-C. Kim, K.A. Jacobson, Bioch. Bioph. Res. Commun., 1997, 232, 317.
• [61] E.G. Paronikyan, A.S. Noravyan, I.A. Dzhagatspanyan, I.M. Nazaryan, R.G. Paronikyan, Pharm. Chem. J., 2002, 36, 465.
• [62] Y. Zhang, B. Illarionov, A. Bacher, M. Fischer, G.I. Georg, Q. Ye, D. Velde, P. E. Fanwick, Y. Song, M. Cushman, J. Org. Chem., 2007, 72, 2769.
• [63] J . Clifford, C. McKay, J.R. Porter, PCT. Int. Appl. WO 2002042264, UK, C.A., 136, 401746, 2002.
• [64] Q. Ding, J.W. Lown, J. Org. Chem., 1999, 64, 7965.
• [65] Ch. Guo, P.R. Guzzo, M. Hadden, B.J. Sargent, L. Yet, Y. Kan, O. Palyha, T.M. Kelly, X. Guan, Bioorg. Med. Chem., 2010, 20, 2785.
• [66] K . Kang, H. Kim, K.I. Kim, Y. Yang, D.Y. Yoon, J.H. Kim, J.H. Ryu, E.J. Noh, S.D. Jeon, J.S. Lim, Bioch. Pharm., 2008, 75, 1054.